Merck & Company, Inc. vs Veeva Systems Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
8.9
Very Bullish
Quality
Health
Growth
Valuation
Sentiment
MRK
Forward P/E of 11.5× is low relative to sector peers.
VEEV
Clean balance sheet with low leverage (0.0× debt-to-equity).
Analyst Consensus
BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $264.46 (+54.1%)
28 analysts
Fundamentals
MRK
VEEV
31.5×
Trailing P/E
31.5×
11.5×
Forward P/E
17.4×
13.6%
Profit Margin
28.4%
76.6%
Gross Margin
75.5%
—
ROE
13.9%
4.9%
Revenue Growth
16.0%
—
Earnings Growth
23.2%
0.28
Beta
1.10
—
Price / Book
—
$277.0B
Market Cap
$28.2B
$73 – $125
52-Week Range
$148 – $311
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →